Results 151 to 160 of about 103,481 (331)

A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.

, 1988
Christiane Mendre, Meghan Rodriquez, Christiane Gueudet, MARIE‐FRANÇOISE LIGNON, Marie‐Christine Galas, Jeanine Laur, P. Worms, Jean Martínez   +7 more
openalex   +1 more source

Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors [PDF]

, 1995
Kevin D. Burris, Mary A. Pacheco, Theresa M. Filtz, Mei‐Ping Kung, Hank F. Kung, Perry B. Molinoff   +5 more
openalex   +1 more source

The Mild Behavioral Impairment Checklist for Parkinson's Disease: An Ancillary Instrument in Cognitive Assessment

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Mild behavioral impairment (MBI) is a syndrome characterized by the later‐life onset of neuropsychiatric symptoms (NPS) and serves as a potential marker for dementia. In Parkinson's disease (PD), MBI has been associated with worse cognition, cortical atrophy, and altered connectivity.
Gabriel D. Pinilla‐Monsalve, Yuan P. Song, Alexandru Hanganu, Zahinoor Ismail, Oury Monchi   +4 more
wiley   +1 more source

Placenta ingestion by rats enhances d- and k-opioid antinociception, but suppresses m-opioid antinociception [PDF]

, 2004
Ingestion of placenta or amniotic fluid produces a dramatic enhancement of centrally mediated opioid antinociception in the rat. The present experiments investigated the role of each opioid receptor type (m, d, k) in the antinociception-modulating ...
DiPirro, Jean M., Kristal, Dr. Mark B.
core  

Pharmacology of reproduction (report 25): Effect of bromocriptine (CB-154), a dopamine agonist on the stimulatory effect of gonadotropin on testicular testosterone levels by the rat

, 1981
Masanao Hirai, Yoshiko Masubuchi, Akiyo Uematsu, Toshio Kumai, K Komoriyama   +4 more
openalex   +1 more source

Dopaminergic Regulation of Progesterone Receptors: Brain D5 Dopamine Receptors Mediate Induction of Lordosis by D1-Like Agonists in Rats [PDF]

, 1996
Ede Marie Apostolakis, János Garai, Charles A. Fox, C. Smith, Stanley J. Watson, James H. Clark, Bert W. O’Malley   +6 more
openalex   +1 more source

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24‐hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor complications.
Jason Aldred, Manon Bouchard, Juan Carlos Martínez‐Castrillo, Michael J. Soileau, Amy M. Spiegel, Lars Bergmann, Resmi Gupta, Megha B. Shah, Pavnit Kukreja, David G. Standaert, Stuart H. Isaacson, Tove Henriksen   +11 more
wiley   +1 more source

Incident mental health episodes after initiation of gabapentinoids vs. dopamine agonists for early-onset idiopathic restless legs syndrome. [PDF]

Psychiatry Res, 2023
Costales B, Vouri SM, Brown JD, Setlow B, Goodin AJ.   +4 more
europepmc   +1 more source

In vivo evidence for NMDA receptor mediated excitotoxicity in a murine genetic model of Huntington Disease [PDF]

, 2008
N-methyl-D-aspartate receptor (NMDAR) mediated excitotoxicity is implicated as a proximate cause of neurodegeneration in Huntington Disease (HD). However, this hypothesis has not been tested rigorously in vivo. NMDAR NR2B-subunits are the predominant NR2
Joe Tsien, Mary Heng, Peter Detloff, Phillip Wang, Roger Albin   +4 more
core   +1 more source

Effects of dopaminergic agonists on rotational behavior and striatal dopamine metabolism following unilateral electrical stimulation of the substantia nigra in the rat

, 1983
Sunao Hata, Hiroshi Watanabe, Kazuo Watanabe   +2 more
openalex   +1 more source